Axsome stock: buy or sell?

AXSM stock price: $45.43 5.06% At close on December 6th, 2019

Updated on:
December 6th, 2019

4

After sliding a bloodcurdling -9.69% yesterday, Axsome closed today at $45.43 and skyrocketed an amazing 5.06%. On Tuesday AXSM boosted a super good 13.13%.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders.

Should I buy Axsome stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

These 2 buy setups are elegible for Axsome stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Axsome Therapeutics stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we collected 12 ratings published for AXSM stock in the last 30 days.

The general sentiment of these ratings is bullish for AXSM stock, with 12 positive ratings.
Is AXSM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-18William Blairn/aOutperform
2019-6-24HC Wainwrightn/aBuy
2019-5-28SunTrust Banksn/aBuy
2019-4-8Svb Leerinkn/aOutperform
2019-4-8Leerink Swannn/aOutperform
2019-3-5HC Wainwrightn/aBuy
2019-3-28BTIG Researchn/aBuy
2019-3-26HC Wainwrightn/aBuy
2019-3-21Cantor Fitzgeraldn/aOverweight
2019-3-21Cantor FitzgeraldOverweightOverweight
2019-3-15HC Wainwrightn/aBuy
2019-3-15Cantor Fitzgeraldn/aOverweight

Axsome stock analysis

Daily outlook

After climbing to all-time highs several times in past weeks, Axsome Therapeutics skyrocketed 5.06% to $45.43.

After several days of continuous hikes in past weeks, Axsome Therapeutics skyrocketed 5.06% to $45.43. Since last October when AXSM stock price broke up the SMA200d line, it gained $27.19 (149.07%). Since SMA50d and SMA100d crossed up on December 4th, AXSM price slid a -0.39%. On Dec 4th, AXSM hit new all time highs, pushing higher previous ATH of $47.24 recorded on Tuesday. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

AXSM stock chart (daily)

Weekly outlook

Axsome Therapeutics ended this week at $45.43 after reaching a new all time high ($47.68) and skyrocketed an exceptional 15.39%. With this, it's been 5 climbing weeks in a row, soaring a 88.22%.

If you observe the weekly chart, price finally broke over the resistance at $24.94 and continued climbing. Since price and SMA40w lines crossed up by mid October, AXSM climbed $27.29 (150.44%). Since this week when SMA10w and SMA20w crossed up, AXSM price gained $6.06 per share (15.39%).

AXSM stock chart (weekly)

Axsome stock price history

Axsome IPO was on November 19th, 2015 at $9.00 per share1. Since then, AXSM stock surged a 404.80%, with a yearly average of 101.20%. If you had invested right after AXSM's IPO a $1,000 in Axsome stock in 2015, it would worth $4,048.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Axsome stock historical price chart

AXSM stock reached all-time highs on December/4 with a price of $47.68.

Axsome stock price target is $21.90

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We detected 9 price forecasts for AXSM stock released in the last month:
AXSM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-24HC WainwrightSet Price Targetn/a$30.00-
2019-4-8Svb LeerinkInitiatesn/a$25.00-
2019-3-5HC WainwrightSet Price Targetn/a$15.00-
2019-3-28BTIG ResearchRaises Targetn/a$25.00-
2019-3-26HC WainwrightSet Price Targetn/a$18.00-
2019-3-21Cantor FitzgeraldReiterates$16.00$25.0056.3%
2019-3-21Cantor FitzgeraldRaises Target$16.00$25.0056.3%
2019-3-15HC WainwrightReiterates$15.00$18.0020%
2019-3-15Cantor FitzgeraldRaises Target$13.00$16.0023.1%
(in average)$15.00$21.9046.0%
The price target for Axsome Therapeutics stock is $21.90, moving in a range between $30.00 and $15.00. In average, analysts' outlook on AXSM price target is positive, upgrading the forecast by a 46.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on March, Axsome . As soon as we get its actual EPS from the earnings report, we will extend this review.
AXSM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.41n/a
2017-Q2-n/a-0.3n/a
2017-Q32017-11-08-0.34-0.27n/a
2017-Q42018-03-07n/a-0.28n/a
2018-Q12018-05-08n/a-0.19n/a
2018-Q22018-08-08-0.32-0.32n/a
2018-Q32018-11-09-0.33-0.31n/a
2018-Q42019-03-14-0.33-0.32n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to , last anual revenues report draw of to M USD. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .

AXSM annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter earnings marked $-9.60 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Axsome Therapeutics sales marked a neutral movement and remained stable a nan%. Looking back to recent quarterly results, Axsome posted 7 positive quarters in a row.
AXSM quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Axsome ownership

When you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Axsome Therapeutics, 27.32% of all outstanding shares are owned by its staff.

In case of Axsome stock, 17.42% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AXSM stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related stocks:

AXSMPDLIPIRS
Market cap$1.6 B$341.4 M$188.6 M
Total shares34.5 M114.2 M55.0 M
Float shares23.8 M96.5 M41.5 M
  - Institutional holdings (%)17.4%95.2%72.8%
  - Insider holdings (%)27.3%2.5%0.2%
Shares in short selling0.0%0.0%0.0%

Axsome summary

Friday, December 6th, 2019
Open$42.57
Close$45.43
Day range$42.44 - $45.68
Previous close$43.24
Session gain5.06%
Average true range$3.10
50d mov avg$26.53
100d mov avg$26.12
200d mov avg$22.33
Daily pattern
Weekly pattern lb01c

Axsome performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Axsome performance to PDL BioPharma and Pieris Pharmaceuticals:
Stock3m6m12m
AXSMAxsome Therapeuti...83.33%106.22%1440.00%
PDLIPDL BioPharma35.29%0.67%0.34%
PIRSPieris Pharmaceut...-22.92%-16.75%-2.28%

Axsome competitors

Choosing a list of competitors for Axsome Therapeutics it's difficult. We selected 2 public companies that are related to and can be considered as competitors of Axsome Therapeutics: